Starovasnik Melissa A.
CIK: 0001877739
Associated companies
Transaction History
| TWST | ▼ Sell | Open Market | 2,500 | $170K | 5/28/2026 | View on chart |
| TWST | ▼ Sell | Open Market | 500 | $31K | 5/26/2026 | View on chart |
| TWST | ▼ Sell | Open Market | 500 | $31K | 4/27/2026 | View on chart |
| TWST | ▼ Sell | Open Market | 1,000 | $51K | 4/1/2026 | View on chart |
| TWST | ▲ Buy | Grant | 5,095 | $0 | 2/5/2026 | View on chart |
| TWST | ▲ Buy | Grant | 4,472 | $0 | 2/5/2025 | View on chart |
| TWST | ▲ Buy | Grant | 5,815 | $0 | 2/6/2024 | View on chart |
| TWST | ▼ Sell | Open Market | 1,732 | $46K | 2/9/2023 | View on chart |
| TWST | ▲ Buy | Grant | 8,212 | $0 | 2/7/2023 | View on chart |
| TWST | ▲ Buy | Grant | 3,491 | $0 | 2/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Twist Bioscience highlighted in AI biofoundry and analyst upgrades
Recent coverage places Twist Bioscience at the center of AI‑driven biofoundry platforms and synthetic antibody library development. Analyst TD Cowen raised its price target to $190, reflecting confidence in the company’s role in these growing markets. The stock also appeared in a portfolio update and a whale‑alert list, indicating heightened investor attention.
Twist Bioscience highlighted in AI biofoundry and analyst upgrades. Recent coverage places Twist Bioscience at the center of AI‑driven biofoundry platforms and synthetic antibody library development. Analyst TD Cowen raised its price target to $190, reflecting confidence in the company’s role in these growing markets. The stock also appeared in a portfolio update and a whale‑alert list, indicating heightened investor attention.